Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
OMCL

OMCL - Omnicell Inc Stock Price, Fair Value and News

27.23USD-1.80 (-6.20%)Market Closed

Market Summary

OMCL
USD27.23-1.80
Market Closed
-6.20%

OMCL Alerts

  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

OMCL Stock Price

View Fullscreen

OMCL RSI Chart

OMCL Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-59.41

Price/Sales (Trailing)

1.13

EV/EBITDA

10.36

Price/Free Cashflow

7.03

OMCL Price/Sales (Trailing)

OMCL Profitability

Operating Margin

82.01%

EBT Margin

-1.52%

Return on Equity

-1.77%

Return on Assets

-0.92%

Free Cashflow Yield

14.23%

OMCL Fundamentals

OMCL Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

-15.3%

Rev. Growth (Qtr)

-4.9%

OMCL Earnings

Earnings (TTM)

-21.0M

Earnings Growth (Yr)

-4.51%

Earnings Growth (Qtr)

-9.05%

Breaking Down OMCL Revenue

Last 7 days

-9.0%

Last 30 days

-10.1%

Last 90 days

-1.7%

Trailing 12 Months

-62.3%

How does OMCL drawdown profile look like?

OMCL Financial Health

Current Ratio

2.38

OMCL Investor Care

Shares Dilution (1Y)

1.87%

Diluted EPS (TTM)

-0.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.1B000
20231.3B1.2B1.2B1.1B
20221.2B1.3B1.3B1.3B
2021914.4M987.5M1.1B1.1B
2020924.2M906.4M891.3M892.2M
2019807.2M835.9M860.5M897.0M
2018746.8M754.4M771.9M787.3M
2017673.5M681.6M691.6M712.7M
2016539.3M599.5M651.0M695.9M
2015455.4M463.1M475.8M484.6M
2014395.2M406.6M425.1M440.9M
2013337.0M355.3M365.0M380.6M
2012252.5M266.9M286.8M314.0M
2011225.4M231.7M239.9M245.5M
20100216.4M219.4M222.4M
2009000213.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Omnicell Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 21, 2024
ghoshal kaushik
acquired
-
-
5,717
-
May 21, 2024
scott bruce e
acquired
-
-
6,177
-
May 21, 2024
seim robin gene
acquired
-
-
6,143
-
May 21, 2024
parrish mark w
acquired
-
-
6,143
-
May 21, 2024
bousa edward peter
acquired
-
-
5,802
-
May 21, 2024
bauer joanne b
acquired
-
-
6,741
-
May 21, 2024
garrett mary
acquired
-
-
6,058
-
May 21, 2024
voynick eileen j.
acquired
-
-
6,058
-
May 15, 2024
nutt brian h.
acquired
-
-
3,218
vp, chief accounting officer
May 15, 2024
spears joseph brian
sold (taxes)
-3,494
29.87
-117
executive advisor

1–10 of 50

Which funds bought or sold OMCL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
17.74
-1,607
8,365
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-129,000
450,000
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.7
-465,865
1,327,660
-%
May 16, 2024
COMERICA BANK
reduced
-24.98
-462,242
645,514
-%
May 16, 2024
Global Financial Private Client, LLC
unchanged
-
-333
1,059
-%
May 16, 2024
Beacon Capital Management, LLC
new
-
877
877
-%
May 16, 2024
JANE STREET GROUP, LLC
added
169
870,828
1,669,940
-%
May 15, 2024
Brevan Howard Capital Management LP
new
-
289,815
289,815
-%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
1.33
-32,450
119,989
-%
May 15, 2024
MARSHALL WACE, LLP
sold off
-100
-1,333,640
-
-%

1–10 of 38

Are Funds Buying or Selling OMCL?

Are funds buying OMCL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OMCL
No. of Funds

Unveiling Omnicell Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.25%
5,571,166
SC 13G/A
Jan 19, 2024
blackrock inc.
17.3%
7,887,234
SC 13G/A
Dec 11, 2023
wellington management group llp
0.26%
116,773
SC 13G/A
Sep 11, 2023
vanguard group inc
10.03%
4,532,732
SC 13G/A
Feb 09, 2023
vanguard group inc
9.92%
4,430,315
SC 13G/A
Feb 06, 2023
wellington management group llp
7.34%
3,277,600
SC 13G/A
Jan 23, 2023
blackrock inc.
12.8%
5,728,315
SC 13G/A
Feb 10, 2022
vanguard group inc
10.79%
4,740,493
SC 13G/A
Feb 04, 2022
wellington management group llp
5.76%
2,531,555
SC 13G/A
Jan 27, 2022
blackrock inc.
15.9%
6,983,442
SC 13G/A

Recent SEC filings of Omnicell Inc

View All Filings
Date Filed Form Type Document
Jun 04, 2024
8-K/A
Current Report
May 24, 2024
8-K
Current Report
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading

Peers (Alternatives to Omnicell Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
457.7B
379.5B
-3.22% 8.59%
29.8
1.21
12.96% -25.81%
94.9B
206.0B
-3.57% 26.64%
24.62
0.46
12.55% -43.95%
89.3B
66.7B
6.37% 20.20%
16.32
1.34
9.59% -4.59%
76.6B
360.9B
8.98% -8.43%
10.46
0.21
9.07% 78.83%
36.8B
155.5B
-10.29% 6.67%
13.46
0.24
6.34% 84.42%
12.6B
14.7B
5.13% 28.66%
15.49
0.86
7.99% 19.23%
12.5B
12.3B
3.74% 45.80%
15.28
1.01
5.77% 58.74%
MID-CAP
8.1B
2.3B
-5.45% -0.01%
28.73
3.55
5.96% 18.29%
6.2B
3.0B
-7.01% -9.23%
-544.71
2.06
10.92% -104.06%
2.2B
1.5B
-5.59% 23.35%
34.9
1.5
19.34% 40.15%
2.0B
3.5B
-13.69% -50.16%
14.21
0.59
-27.67% -62.40%
SMALL-CAP
1.9B
1.1B
5.75% 24.78%
28.95
1.75
11.45% 30.74%
1.3B
3.0B
-6.99% 58.71%
-7.38
0.42
4.98% 4.88%
53.7M
-
-1.46% -24.54%
-3.55
-
- -1.05%
20.7M
21.6M
-7.10% 23.86%
40.75
0.96
9.04% -57.88%

Omnicell Inc News

Latest updates
MarketBeat5 hours ago
Zacks Investment Research03 Jun 202403:00 pm
Yahoo Finance2 months ago

Omnicell Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-4.9%246259299299291298348331319311296273252249214200230248229217203
Gross Profit-12.1%93.0010513213412512215915815014914713612212497.0083.0011012411210497.00
Operating Expenses-11.1%11412912812714816014114614513811710710310387.0090.0097.0010188.0085.0084.00
  S&GA Expenses-9.4%92.0010210410412513211511912011698.0089.0087.0088.0071.0069.0079.0082.0071.0068.0068.00
  R&D Expenses-17.8%22.0027.0024.0023.0023.0028.0025.0026.0025.0022.0019.0018.0016.0015.0015.0021.0019.0019.0017.0017.0016.00
EBITDA Margin8.0%0.06*0.06*0.04*0.05*0.05*0.07*0.10*0.10*0.11*0.12*0.13*0.13*---------
Income Taxes47.8%-2.15-4.132.009.00-6.20-7.111.002.00-3.24-7.18-5.993.00-1.21-2.502.00-2.520.00-0.123.001.008.00
Earnings Before Taxes3.7%-17.83-18.527.0012.00-21.18-35.5117.0011.005.007.0023.0023.0013.0014.0011.00-6.8211.0022.0023.0017.0011.00
EBT Margin13.3%-0.02*-0.02*-0.03*-0.02*-0.02*0.00*0.03*0.04*0.05*0.06*0.07*0.06*---------
Net Income-9.1%-15.68-14.376.003.00-15.00-28.4117.009.008.0014.0029.0020.0014.0016.009.00-4.3011.0022.0020.0016.003.00
Net Income Margin-7.5%-0.02*-0.02*-0.03*-0.02*-0.01*0.00*0.04*0.05*0.06*0.07*0.07*0.06*---------
Free Cashflow39.7%41.0029.0046.0061.003.0068.008.00-19.16-27.4849.0036.0066.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets2.6%2,2842,2272,2222,1942,2512,2112,1802,1312,1232,1422,0511,9611,8871,8251,7191,2221,2321,2411,2441,1971,177
  Current Assets6.7%990928914881935882849788776781889984904829963465478483477430414
    Cash Equivalents9.5%51246844739934035326624526534948261454849062913410412713787.0077.00
  Inventory-6.0%10311011613114114814715013712010410196.0096.00103114113108106104104
  Net PPE0.4%10910910710398.0094.0088.0082.0077.0071.0065.0062.0061.0059.0058.0058.0053.0054.0055.0053.0052.00
  Goodwill-0.1%735736734736735734731734740739616499499499160335335337335336336
Liabilities5.5%1,0951,0381,0341,0301,1081,0811,0441,0391,048996940908876857801335353396437424447
  Current Liabilities13.2%416368369370454428377374951876339317292276234237248237228211211
  Long Term Debt------------------50.0077.0077.0097.00
    LT Debt, Non Current------------------50.0077.0077.0097.00
Shareholder's Equity0.0%1,1891,1891,1871,1641,1431,1301,1351,0931,0751,1471,1111,0531,011968918887879845808773730
  Retained Earnings-4.2%355370385379376391419402393369355325305291274266270259237217201
  Additional Paid-In Capital1.5%1,1391,1221,1101,0891,0731,0471,0319989831,0251,003971950920892821808781770753725
Shares Outstanding0.8%46.0046.0045.0045.0045.0045.0044.0044.0044.0043.0044.0043.00---------
Float----3,300---5,000---6,500---3,000---3,500-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations30.0%49,95338,41457,00772,90312,77082,15321,175-9,551-15,99659,63242,98971,77357,41576,44836,68747,50425,23134,82056,42827,26326,497
  Share Based Compensation-29.1%8,64112,18714,98214,08914,04217,51617,31017,21316,20814,68313,66613,03911,77211,66311,02411,35110,6598,8748,5058,2608,410
Cashflow From Investing0.3%-12,340-12,372-14,187-14,817-13,640-17,252-15,867-6,817-18,733-192,385-193,631-13,350-13,132-236,692-9,961-19,438-13,775-14,903-14,811-15,253-16,697
Cashflow From Financing-9.2%11,92613,1302,8253,6033,8623,5629,056-1,452-32,1196,66618,2846,81415,59920,399468,1781,458-33,766-30,5248,628-1,405-178
  Buy Backs---------52,210-----53,035------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

OMCL Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues$ 246,151$ 290,629
Cost of revenues153,528165,600
Gross profit92,623125,029
Operating expenses:  
Research and development22,05622,878
Selling, general, and administrative92,414125,114
Total operating expenses114,470147,992
Loss from operations(21,847)(22,963)
Interest and other income (expense), net4,0161,781
Loss before income taxes(17,831)(21,182)
Benefit from income taxes(2,155)(6,182)
Net loss$ (15,676)$ (15,000)
Net loss per share:  
Basic (in dollars per share)$ (0.34)$ (0.33)
Diluted (in dollars per share)$ (0.34)$ (0.33)
Weighted-average shares outstanding:  
Basic (in shares)45,73244,887
Diluted (in shares)45,73244,887
Product revenues  
Revenues$ 133,295$ 185,715
Cost of revenues92,441109,527
Services and other revenues  
Revenues112,856104,914
Cost of revenues$ 61,087$ 56,073

OMCL Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 512,364$ 467,972
Accounts receivable and unbilled receivables, net of allowances of $6,463 and $5,564, respectively248,512252,025
Inventories103,466110,099
Prepaid expenses26,58525,966
Other current assets98,99171,509
Total current assets989,918927,571
Property and equipment, net109,034108,601
Long-term investment in sales-type leases, net43,90942,954
Operating lease right-of-use assets26,53124,988
Goodwill735,357735,810
Intangible assets, net205,115211,173
Long-term deferred tax assets37,38332,901
Prepaid commissions50,19152,414
Other long-term assets86,31790,466
Total assets2,283,7552,226,878
Current liabilities:  
Accounts payable43,14545,028
Accrued compensation41,44651,754
Accrued liabilities167,187149,276
Deferred revenues164,586121,734
Total current liabilities416,364367,792
Long-term deferred revenues65,19558,622
Long-term deferred tax liabilities1,4931,620
Long-term operating lease liabilities34,56833,910
Other long-term liabilities7,0996,318
Convertible senior notes, net570,439569,662
Total liabilities1,095,1581,037,924
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued00
Common stock, $0.001 par value, 100,000 shares authorized; 56,207 and 55,822 shares issued; 45,924 and 45,539 shares outstanding, respectively5656
Treasury stock at cost, 10,283 shares outstanding, respectively(290,319)(290,319)
Additional paid-in capital1,139,0101,122,292
Retained earnings354,681370,357
Accumulated other comprehensive loss(14,831)(13,432)
Total stockholders’ equity1,188,5971,188,954
Total liabilities and stockholders’ equity$ 2,283,755$ 2,226,878
OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.
 CEO
 WEBSITEomnicell.com
 INDUSTRYHealthcare Plans
 EMPLOYEES3780

Omnicell Inc Frequently Asked Questions


What is the ticker symbol for Omnicell Inc? What does OMCL stand for in stocks?

OMCL is the stock ticker symbol of Omnicell Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omnicell Inc (OMCL)?

As of Thu Jun 13 2024, market cap of Omnicell Inc is 1.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMCL stock?

You can check OMCL's fair value in chart for subscribers.

What is the fair value of OMCL stock?

You can check OMCL's fair value in chart for subscribers. The fair value of Omnicell Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omnicell Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMCL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omnicell Inc a good stock to buy?

The fair value guage provides a quick view whether OMCL is over valued or under valued. Whether Omnicell Inc is cheap or expensive depends on the assumptions which impact Omnicell Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMCL.

What is Omnicell Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, OMCL's PE ratio (Price to Earnings) is -59.41 and Price to Sales (PS) ratio is 1.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMCL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Omnicell Inc's stock?

In the past 10 years, Omnicell Inc has provided -0.001 (multiply by 100 for percentage) rate of return.